The ClearPlasma device is a non-pyrogenic, sterile, single-use device designed to remove Plasminogen and tPA from blood products, thus enabling the reduction of fibrin clot breakdown (fibrinolysis) occurring during massive bleeding. The device utilizes the chemical affinity of plasminogen to a specific ligand through its binding sites. When plasma runs through the resin bed, the plasminogen encounters the ligand that is covalently bound to the resin, and specifically binds to it. The plasma, now depleted from plasminogen, continues to flow through the device and is collected in new plasma bag ready for transfusion.
ClearPlasma™ effectively reduces bleeding in more than 55%
Plas-Free’s Ammonia Adsorption Plasma Column (AAPC-300) device is a non-pyrogenic, sterile, single-use device designed to remove ammonia from the blood stream. The AAPC-300 effectively and specifically extracts ammonia from plasma fraction, thus enabling the reduction of ammonia levels during hepatic encephalopathy (HE). Neurological injury is non-reversible, thus time is critical in the treatment of hyperammonemia. The APPC-300 can reduce the levels of ammonia in less than 1.5 hours thereby preventing significant accumulated neurologic injury. This contrasts with the pharmacokinetics of drugs that can take few hours and subsequently cause additional neurologic injury.
INNOVATIVE PLASMA FILTRATION TECHNOLOGY
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 882231